Singapore Grants Interim Approval For Modernas Bivalent COVID 19 Booster Vaccine
The vaccine has been authorised for use as a booster shot in individuals aged 18 years and above who have received the primary series of COVID-19 vaccinations, the city-state's Health Sciences Authority said. Singapore on Wednesday granted interim authorisation for a bivalent COVID-19 booster vaccine made by Moderna, the government said in a statement. The vaccine has been authorised for use as a booster shot in individuals aged 18 years and above who have received the primary series of COVID-19 vaccinations, the citystate's Health Sciences Authority said. Moderna's bivalent vaccine contains mRNA designed to target two different coronavirus variants - the original variant from 2020 and the Omicron variant that was circulating widely last winter.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
